IgG4-related sclerosing cholangitis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:447764K83.0
Who is this for?
Show terms as
1FDA treatments25Specialists8Treatment centers1Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

IgG4-related sclerosing cholangitis (IgG4-SC) is a rare inflammatory disease that affects the bile ducts — the tubes that carry bile from the liver to the small intestine. It is part of a larger group of conditions called IgG4-related disease (IgG4-RD), where the immune system produces too many of a certain type of antibody called IgG4, leading to inflammation and scarring (fibrosis) in various organs. In IgG4-SC, this process mainly targets the bile ducts, causing them to narrow and become blocked over time. The most common symptoms include yellowing of the skin and eyes (jaundice), dark urine, pale stools, itching, and abdominal pain. Many people also experience weight loss and fatigue. Because the bile ducts are closely connected to the pancreas, IgG4-SC often occurs alongside a condition called autoimmune pancreatitis (AIP), and the two are frequently diagnosed together. The disease is sometimes mistaken for bile duct cancer or primary sclerosing cholangitis (PSC), which can delay diagnosis. The good news is that IgG4-SC usually responds very well to treatment with corticosteroids, particularly prednisone. Most patients see significant improvement after starting steroids. However, relapses are common, and some people need long-term treatment to keep the disease under control. Other medications such as rituximab or azathioprine may be used to help maintain remission and reduce steroid side effects. Early diagnosis and treatment are important to prevent permanent scarring of the bile ducts and liver damage.

Key symptoms:

Yellowing of the skin and whites of the eyes (jaundice)Dark, tea-colored urinePale or clay-colored stoolsItchy skinUpper abdominal pain or discomfortUnexplained weight lossFatigue and low energyNauseaFever (less common)Swelling or tenderness in the abdomenSigns of liver problems such as elevated liver enzymes on blood tests

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

Treatments

1 available

WEGOVY

SEMAGLUTIDE· Novo Nordisk■ Boxed Warning

To reduce excess body weight and maintain weight reduction long term in adults with overweight in the presence of at least one weight-related comorbid condition

No actively recruiting trials found for IgG4-related sclerosing cholangitis at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the IgG4-related sclerosing cholangitis community →

Specialists

25 foundView all specialists →
DI
Dai Inoue
DUNWOODY, GA
Specialist
2 IgG4-related sclerosing cholangitis publications
TK
Terumi Kamisawa
Specialist
3 IgG4-related sclerosing cholangitis publications
KN
Kenji Notohara
Specialist
2 IgG4-related sclerosing cholangitis publications
YK
Yusuke Kurita
Specialist
2 IgG4-related sclerosing cholangitis publications
AT
Atsushi Tanaka
Specialist
2 IgG4-related sclerosing cholangitis publications
HT
Hajime Takikawa
Specialist
2 IgG4-related sclerosing cholangitis publications
MU
Michiaki Unno
Specialist
2 IgG4-related sclerosing cholangitis publications
SK
Shigeyuki Kawa
Specialist
2 IgG4-related sclerosing cholangitis publications
SN
Seiji Nakamura
Specialist
2 IgG4-related sclerosing cholangitis publications
AN
Akira Nakamura
SEAL BEACH, CA
Specialist
2 IgG4-related sclerosing cholangitis publications
QL
Qiaoyan Liu
Specialist
1 IgG4-related sclerosing cholangitis publication
TN
Takahiro Nakazawa
Specialist
8 IgG4-related sclerosing cholangitis publications
IN
Itaru Naitoh
Specialist
7 IgG4-related sclerosing cholangitis publications
KK
Kensuke Kubota
Specialist
4 IgG4-related sclerosing cholangitis publications
AM
Atsushi Masamune
Specialist
4 IgG4-related sclerosing cholangitis publications
MM
Mark D Topazian, MD
ROCHESTER, MN
Specialist
PI on 1 active trial
AM
Arezou Khosroshahi, MD
ATLANTA, GA
Specialist
PI on 1 active trial1 IgG4-related sclerosing cholangitis publication
LP
Lewis R Roberts, MB, ChB, PhD
Specialist
PI on 1 active trial
JZ
Jian Zhu
Specialist
PI on 1 active trial404 IgG4-related sclerosing cholangitis publications
LZ
Lizhi Zhang
ROCHESTER, MN
Specialist
2 IgG4-related sclerosing cholangitis publications
MK
Myung-Hwan Kim
Specialist
2 IgG4-related sclerosing cholangitis publications
SY
Satoshi Yamamoto
SAN FRANCISCO, CA
Specialist
2 IgG4-related sclerosing cholangitis publications
PS
Puja Sakhuja
Specialist
2 IgG4-related sclerosing cholangitis publications
SG
Surbhi Goyal
Specialist
2 IgG4-related sclerosing cholangitis publications
RT
Ruqi Tang
Specialist
2 IgG4-related sclerosing cholangitis publications

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

1 resources
WEGOVY(SEMAGLUTIDE)Novo Nordisk

Travel Grants

No travel grants are currently matched to IgG4-related sclerosing cholangitis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open IgG4-related sclerosing cholangitisForum →

No community posts yet. Be the first to share your experience with IgG4-related sclerosing cholangitis.

Start the conversation →

Latest news about IgG4-related sclerosing cholangitis

1 articles
NewsFDAMar 19, 2026
FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide
The U.S. Food and Drug Administration today approved a new higher dose (7.2 mg) of Wegovy (semaglutide) injection for weight loss and long-term maintenance of w
See all news about IgG4-related sclerosing cholangitis

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.How confident are you in the diagnosis of IgG4-SC, and have other conditions like bile duct cancer or primary sclerosing cholangitis been ruled out?,What organs besides my bile ducts are affected, and do I need to be checked for IgG4-related disease elsewhere in my body?,What is my treatment plan, and how long will I need to take steroids?,What are the signs that my disease is relapsing, and what should I do if I notice them?,Are there steroid-sparing medications I should consider to reduce long-term steroid side effects?,How often will I need follow-up appointments and imaging to monitor my bile ducts and liver?,Is there a clinical trial or specialist center for IgG4-related disease that I should be referred to?

Common questions about IgG4-related sclerosing cholangitis

What is IgG4-related sclerosing cholangitis?

IgG4-related sclerosing cholangitis (IgG4-SC) is a rare inflammatory disease that affects the bile ducts — the tubes that carry bile from the liver to the small intestine. It is part of a larger group of conditions called IgG4-related disease (IgG4-RD), where the immune system produces too many of a certain type of antibody called IgG4, leading to inflammation and scarring (fibrosis) in various organs. In IgG4-SC, this process mainly targets the bile ducts, causing them to narrow and become blocked over time. The most common symptoms include yellowing of the skin and eyes (jaundice), dark uri

How is IgG4-related sclerosing cholangitis inherited?

IgG4-related sclerosing cholangitis follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does IgG4-related sclerosing cholangitis typically begin?

Typical onset of IgG4-related sclerosing cholangitis is adult. Age of onset can vary across affected individuals.

Which specialists treat IgG4-related sclerosing cholangitis?

25 specialists and care centers treating IgG4-related sclerosing cholangitis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for IgG4-related sclerosing cholangitis?

1 patient support program are currently tracked on UniteRare for IgG4-related sclerosing cholangitis. See the treatments and support programs sections for copay assistance, eligibility, and contact details.